Abstract 2388
Background
EV-201 (NCT03219333) is a single-arm, 2-cohort study of EV in mUC patients treated with prior CPI and platinum-containing chemotherapy (Cohort 1) or a CPI and no prior chemotherapy and are cisplatin-ineligible (Cohort 2). The confirmed ORR rate was 44%. Patient-reported outcome (PRO) measures were included in EV-201 as exploratory endpoints. Our objective was to explore the impact of EV on QoL in Cohort 1 of EV-201.
Methods
Two validated instruments were included (EORTC QLQ-C30 v3 and EQ-5D-3L). The 30-item EORTC QLQ-C30 measures functioning, symptoms, and financial impact with scores ranging from 0 to 100. The 5-item EQ-5D measures mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted to a score ranging from 0 to 1, with 0 representing death and 1 representing perfect health. The EQ-5D also records self-rated health status on a 0-100 visual analogue scale (VAS). Assessments were completed at baseline and start of each cycle.
Results
Of 125 subjects from Cohort 1, 120 (96%) received EV and completed both instruments at baseline. Across all cycles, >86% of subjects with available data at each cycle completed both instruments. QLQ-C30 domain scores, inclusive of general QoL, functioning, and symptom scores, remained stable over time. Some domains demonstrated trends toward improvement across the study period (e.g. emotional, role, and social functioning, as well as pain, fatigue, appetite loss, constipation, and diarrhea) (Table). EQ-5D utility and VAS scores also remained stable throughout the treatment period. Variability and small sample size limit definitive conclusions.Table:
921P Patient reported outcomes at baseline, cycle 5, and cycle 10
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Mean (SD) Scores | Baseline n = 120 | Cycle 5 n = 59 | Cycle 10 n = 12 |
---|---|---|---|
Global quality of life | 63.0 (20.8) | 65.4 (19.8) | 69.4 (25.0) |
Functional domains | |||
Physical functioning | 76.4 (20.8) | 78.9 (16.7) | 92.2 (8.4) |
Role functioning | 73.3 (27.8) | 74.3 (23.2) | 84.7 (11.1) |
Emotional functioning | 81.7 (18.4) | 85.3 (17.7) | 86.8 (11.5) |
Cognitive functioning | 85.3 (19.2) | 83.9 (18.8) | 93.1 (13.2) |
Social functioning | 73.5 (26.1) | 76.3 (25.7) | 86.1 (21.1) |
Symptom scales | |||
Fatigue | 35.3 (22.9) | 36.4† (21.1) | 17.6† (12.9) |
Nausea and vomiting | 9.0 (15.9) | 5.5† (13.0) | 1.4† (4.8) |
Dyspnoea | 16.9 (23.4) | 17.5† (27.5) | 13.9† (17.2) |
Insomnia | 27.2 (28.7) | 22.4† (22.8) | 11.1† (16.4) |
Appetite loss | 24.7 (30.1) | 23.6† (25.8) | 11.1† (25.9) |
Constipation | 24.4 (30.5) | 13.2† (20.7) | 8.3† (15.1) |
Diarrhea | 8.9 (18.2) | 6.8† (16.1) | 5.6† (13.0) |
Pain | 29.9 (28.7) | 22.3† (26.6) | 4.2† (7.5) |
Financial difficulties | 18.2 (30.0) | 19.2† (27.8) | 27.8† (27.8) |
EuroQol 5 dimension 3 level Questionnaire (EQ-5D-3L) Mean (SD) scores | |||
Visual analogue scale (VAS) | 66.9 (20.5) | 67.1 (20.8) | 78.4 (27.3) |
Utility score | 0.795 (0.163) | 0.809 (0.148) | 0.910 (0.102) |
Higher scores represent a positive effect except for symptom domains as marked with †, where higher scores represent greater symptom burden. SD – standard deviation.
Conclusions
Findings demonstrate that QoL is either maintained or improved for patients on treatment with EV, which complement the efficacy and safety results from EV-201 Cohort 1.
Clinical trial identification
NCT03219333.
Editorial acknowledgement
Lisa Bloudek of Curta, funded by Seattle Genetics. Shang-Ying Liang of Seattle Genetics provided statistical support and QC of results.
Legal entity responsible for the study
Seattle Genetics Inc.
Funding
Seattle Genetics, Inc. and Astellas Pharma, Inc.
Disclosure
B.A. McGregor: Advisory / Consultancy: Astellas Pharma Inc.; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Decibel Therapeutics; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Exelixis; Advisory / Consultancy: Genentech; Advisory / Consultancy: Janssen; Advisory / Consultancy: Nextar; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy: AstraZeneca; Research grant / Funding (self), Research grant / Funding (institution): Calithera Biosciences. P.H. O’Donnell: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Merck; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Shareholder / Stockholder / Stock options: Allergan; Shareholder / Stockholder / Stock options: PrescriptIQ; Honoraria (self), Honoraria (institution): Astellas Pharma Inc.; Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution): Genentech; Honoraria (self), Honoraria (institution): Harrison Consulting Group; Honoraria (self), Honoraria (institution): Inovio; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution), Non-remunerated activity/ies, Other Relationship: Janssen; Honoraria (self), Honoraria (institution): Kantar Health; Research grant / Funding (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Honoraria (institution): OncLive; Honoraria (self), Honoraria (institution): Parexel; Honoraria (self), Honoraria (institution): Quintiles; Research grant / Funding (self), Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (self), Research grant / Funding (institution): Acerta; Non-remunerated activity/ies, Other Relationship: Advance Medical; Licensing / Royalties: Named as co-inventor on pending patent for a genomic prescribing system for medication prescribing. A. Balar: Advisory / Consultancy: Astellas Pharma Inc.; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Cerulean Pharma; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Genentech; Advisory / Consultancy: Incyte; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Merck; Advisory / Consultancy: Pfizer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics. D.P. Petrylak: Advisory / Consultancy: Astellas Pharma Inc.; Research grant / Funding (self), Research grant / Funding (institution): Astellas Medivation; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Bayer; Advisory / Consultancy: Bellicum Pharma; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Dendreon; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Ferring; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Johnson&Johnson; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Millennium; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): MedImmune; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Tyme; Research grant / Funding (self), Research grant / Funding (institution): Agensys; Research grant / Funding (self), Research grant / Funding (institution): Clovis Onc; Research grant / Funding (self), Research grant / Funding (institution): Endocyte; Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Lilly; Advisory / Consultancy: Medivation; Research grant / Funding (self), Research grant / Funding (institution): Genentech; Research grant / Funding (self), Research grant / Funding (institution): Innocrin Pharma; Research grant / Funding (self), Research grant / Funding (institution): Merck; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Progenics; Research grant / Funding (self), Research grant / Funding (institution): Sotio. J.E. Rosenberg: Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Agensys; Honoraria (self), Honoraria (institution): AstraZeneca; Advisory / Consultancy: AstraZeneca/MedImmune; Advisory / Consultancy: Bayer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Inovo Pharmaceuticals; Advisory / Consultancy: Lilly; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Merck; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Seattle Genetics; Shareholder / Stockholder / Stock options: Illumina; Honoraria (self), Honoraria (institution): Medcape; Honoraria (self), Honoraria (institution): Peerview; Honoraria (self), Honoraria (institution): UpToDate; Honoraria (self), Honoraria (institution): Vindico; Licensing / Royalties: Predictor of Platinum sensitivity; Research grant / Funding (self), Research grant / Funding (institution): Incyte; Research grant / Funding (self), Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Oncogenex; Research grant / Funding (self), Research grant / Funding (institution): Viralytics. E. Yu: Advisory / Consultancy: Amgen; Advisory / Consultancy: AstraZeneca; Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Churchill Pharma; Advisory / Consultancy, Research grant / Funding (institution): Dendreon; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Incyte; Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: QED Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy: Tolmar; Advisory / Consultancy: Pharmacyclics; Research grant / Funding (institution): Agensys; Research grant / Funding (self): Daiichi Sankyo. D.I. Quinn: Full / Part-time employment: University of Southern California; Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: Dendreon; Advisory / Consultancy: Exelixis; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Sanofi. S.N. Shah: Full / Part-time employment: Astellas Pharma Inc. J. Pinelli: Shareholder / Stockholder / Stock options, Full / Part-time employment: Seattle Genetics. Z. Hepp: Shareholder / Stockholder / Stock options, Full / Part-time employment: Seattle Genetics. M. Galsky: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Genentech; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Dracen; Advisory / Consultancy: Dragonfly Therapeutics; Advisory / Consultancy: Astellas; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Janssen; Research grant / Funding (institution): Dendreon; Research grant / Funding (institution): Roche/Genentech.
Resources from the same session
4096 - Patient experience and use of an intervention combining nurse-led telephone and technologies for the monitoring of oral cancer medication
Presenter: Marie Ferrua
Session: Poster Display session 3
Resources:
Abstract
6042 - Harnessing nurse leadership to implement a project for electronic scheduling of chemotherapy
Presenter: Emma Masters
Session: Poster Display session 3
Resources:
Abstract
3123 - Turkish Cancer Patients’ Preference for Information and Communication Technologies
Presenter: Esra ildes
Session: Poster Display session 3
Resources:
Abstract
6062 - Unmet Needs in Oncology Research related to radiological response evaluation: a multi-center survey in three European countries
Presenter: Sophie Nisse Durgeat
Session: Poster Display session 3
Resources:
Abstract
6109 - A program implementation to facilitate intraoperative brachytherapy between hospitals
Presenter: Marc Garcia Casellas
Session: Poster Display session 3
Resources:
Abstract
1772 - Using Mobile-Based Health Care Applications Outcomes: Mini Systematic Review
Presenter: Aydanur Aydin
Session: Poster Display session 3
Resources:
Abstract
2792 - Evaluation of an education program for cancer patients receiving chemotherapy
Presenter: Iraqi Amina
Session: Poster Display session 3
Resources:
Abstract
3715 - iGestSaúde: Application for self-management of symptoms during chemotherapy treatment
Presenter: Bruno Magalhaes
Session: Poster Display session 3
Resources:
Abstract
3854 - Palliative care requirements of cancer patients and investigation of knowledge and expectations related to palliative care of the patients and their families
Presenter: Ozlem Topkaya
Session: Poster Display session 3
Resources:
Abstract
4997 - Hospice care, what to expect? An exploration of the expectation of future hospice patients
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract